I posted this on the Noxopharm board, but it is equally relevant here.
Do I detect a modest uptick in the SP (of NOX)? I wonder whether the buyers expect the SP to increase on Thursday, when Nyrada lists?
Nyrada has developed an oral PCSK9 inhibitor, much to the chagrin of Big Pharma - who tried, and failed. It also has a drug that is expected to alleviate the effects of stroke and concussion and sound damage. My guess is that these drugs will be of great interest to other companies, but I hope that Nyrada plays hard-to-get. However it pans out, the future looks promising for Nyrada AND for Noxopharm, who will hold 40% of NYR, fully diluted.
NYR Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
